Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_02284 |
| Species: | Homo sapiens |
| Position : | chr1:214150511-214151337 |
| Year: | 2015 |
| Title: | GATA2 is required for lymphatic vessel valve development and maintenance. |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | Lymphedema |
| PMID: | 26214525 |
| MONDO: | MONDO:0019297 |
| Tissue: | lymphatic vessel |
| Tissue Ontology ID: | UBERON:0001473 |
| Cell Source: | K-562 |
| CVCL ID: | CVCL_0004 |
| Experiment Type: | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| High Throughput Method: | ChIP-seq |
| Low Throughput Method: | Luciferase reporter assay; Reporter assay; ChIP-qPCR/ChIP |
| Target gene : | PROX1 |
| TF name : | FOXC2 |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|
| Enhancer ID | Position | Tissue | Cell | Disease |
|---|---|---|---|---|
| E_02200 | chr1:214150511-214151337 | dermis | endothelial cell | lymphedema |
| E_02271 | chr1:214150511-214151337 | dermis | endothelial cell | lymphedema |
| E_02272 | chr1:214150511-214151337 | dermis | endothelial cell | lymphedema |
| E_02285 | chr1:214150511-214151337 | lymphatic vessel | NA | Lymphedema |
| E_02286 | chr1:214150511-214151337 | lymphatic vessel | NA | Lymphedema |
| E_02266 | chr1:214150857-214151185 | lymphatic vessel | endothelial cell | acute myeloid leukemia |
| E_02273 | chr1:214150857-214151185 | lymphatic vessel | endothelial cell | acute myeloid leukemia |
| E_02274 | chr1:214150857-214151185 | lymphatic vessel | endothelial cell | acute myeloid leukemia |
| E_02275 | chr1:214150857-214151185 | lymphatic vessel | endothelial cell | acute myeloid leukemia |
| E_02276 | chr1:214150857-214151185 | lymphatic vessel | endothelial cell | acute myeloid leukemia |
| E_02277 | chr1:214150857-214151185 | lymphatic vessel | endothelial cell | acute myeloid leukemia |